Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Emerging Markets Stock Index Fund ETF (VWO) vs GeneDx Holdings Corp (WGS) Price & Performance

Vanguard Emerging Markets Stock Index Fund ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Vanguard Emerging Markets Stock Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Emerging Markets Stock Index Fund ETF trades at $60.97, while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

VWOWGS
52-Week High
$61.44$167.51
52-Week Low
$52.42$34.51
Market Cap
$2.56B
Sector
Technology
Enterprise Value
$2.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Emerging Markets Stock Index Fund ETF

VWO trades at $61.245, down 0.32% on the day, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing stakes recently. News highlights robust emerging markets performance and record capital inflows, though expense ratios and China exposure remain focal points for investors.

The outlook for VWO is positive given institutional buying and favorable EM trends, but risks include currency volatility and concentrated country weights. Upside hinges on sustained EM outperformance versus developed markets, while any China downturn could pressure returns.

GeneDx Holdings Corp

WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.

Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

About Vanguard Emerging Markets Stock Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.

Read more on VWO

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS